Ablavar, Ablavar (previously vasovist)(gadofosveset)
Ablavar, Vasovist (gadofosveset) is a small molecule pharmaceutical. Gadofosveset was first approved as Ablavar (previously vasovist) on 2005-10-03. It has been approved in Europe to treat magnetic resonance angiography.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadofosveset trisodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ABLAVAR | Lantheus Medical Imaging | N-021711 DISCN | 2008-12-22 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vasovist | 2009-01-02 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9583 | Injection, gadofosveset trisodium, 1 ml |
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | 1 | 1 | — | 3 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | — | 2 | — | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 2 | — | 2 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | 1 | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | — | — | 1 | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | — | 1 | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | 2 | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | — | 2 | 3 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | 2 | 3 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | 1 | — | — | — | 2 | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | — | — | — | — | — | — | 2 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 2 | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 1 | 1 |
| Hemangioma | D006391 | — | D18.0 | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | — | 1 | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 1 | 1 |
| Rectal neoplasms | D012004 | — | — | — | — | — | — | 1 | 1 |
| Neoplasm staging | D009367 | — | — | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gadofosveset |
| INN | gadofosveset |
| Description | Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form. It acts as a blood pool agent by binding to human serum albumin. The manufacturer (Lantheus Medical) discontinued production in 2017 due to poor sales.
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 193901-90-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1908843 |
| ChEBI ID | — |
| PubChem CID | 11672461 |
| DrugBank | DB06705 |
| UNII ID | 9430ZR8ZAN (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 850 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vasovist
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
48 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use